Background {#sec1-0300060518777812}
==========

Methicillin-resistant *Staphylococcus aureus* (MRSA), which was first reported in 1961 in the UK, is a major cause of healthcare-associated infection throughout the world.^[@bibr1-0300060518777812]^ Patients with healthcare-associated MRSA infections have an increased risk of mortality both prior to and after discharge, require longer hospital stays, and accumulate greater medical costs.^[@bibr2-0300060518777812][@bibr3-0300060518777812]--[@bibr4-0300060518777812]^ During 2011 in the United States, an estimated 80,461 invasive MRSA infections occurred, 48,353 of which were healthcare-associated community-onset infections and 14,156 of which were hospital-onset infections.^[@bibr5-0300060518777812],[@bibr6-0300060518777812]^ MRSA infections are associated with an estimated 11,285 deaths per year in the United States.^[@bibr5-0300060518777812],[@bibr6-0300060518777812]^ The prevalence of MRSA infection is likely to be much higher in intensive care units (ICUs). In one study, the healthcare-associated MRSA infection rate was 1.64 infections per 1000 patient-days in the ICU and 0.47 infections per 1000 patient-days in non-ICU settings.^[@bibr7-0300060518777812]^ In light of the fact that many patients are already MRSA-positive on ICU admission and that the majority of MRSA infections are acquired while patients are receiving healthcare, it has been suggested that an important measure in mitigating MRSA spread in the ICU is the routine collection of active surveillance cultures (ASCs). However, some studies have found that such measures are ineffective.^[@bibr8-0300060518777812],[@bibr9-0300060518777812]^

MRSA was first reported in mainland China in the 1980s.^[@bibr10-0300060518777812]^ A limited number of studies have demonstrated that 29.2% of all *S. aureus* infections are MRSA infections, and patients who have been infected with MRSA have longer hospital stays and a higher risk of mortality.^[@bibr11-0300060518777812],[@bibr12-0300060518777812]^ Although several small-scale studies examining the prevalence of MRSA colonization on ICU admission have been published in China, whether MRSA-carrying patients are more likely to develop MRSA infections during their hospitalization remains unknown. A previous study that took place in the same hospital in which our study was conducted showed a high degree of genetic relatedness between their patients and clinical MRSA isolates.^[@bibr13-0300060518777812]^ In the present study, routine MRSA screening was performed in a general ICU to examine the prevalence and risk factors associated with nasal MRSA colonization among ICU patients on admission to the ICU and during their ICU stay.

Methods {#sec2-0300060518777812}
=======

Study population {#sec3-0300060518777812}
----------------

This prospective study was carried out in a general 50-bed ICU at West China Hospital, which is a 4300-bed university hospital in western China. From 1 January 2011 to 31 December 2013, all patients who were admitted to the ICU were enrolled in the study except those with a known MRSA infection on ICU admission. Nasal swabs for MRSA screening were collected from patients within 48 hours of admission; they were also collected at discharge for patients having stayed in the ICU for longer than 3 days. The study population is shown in [Figure 1](#fig1-0300060518777812){ref-type="fig"}.

![Description of the study population. Data are presented as n (%) of patients. ICU, intensive care unit; MRSA, methicillin-resistant *Staphylococcus aureus*; MRSAI, methicillin-resistant *Staphylococcus aureus* infection.](10.1177_0300060518777812-fig1){#fig1-0300060518777812}

ICU nurses collected the swab samples after receiving training by microbiologists and infection control practitioners. For patients with multiple ICU admissions during a single hospitalization period, only their first ICU admission was included. Demographic data such as age, sex, reason for ICU admission, existence of underlying diseases, length of stay (LOS) in the ICU, and mortality in the ICU were retrieved from the patients' medical records.

Microbiological surveillance {#sec4-0300060518777812}
----------------------------

Surveillance cultures were plated on ChromID MRSA-Select agar plates (bioMérieux, Marcy-l\'Étoile, France) and incubated at 35°C for 18 to 24 hours. Clinical samples from patient infection sites were tested by hospital microbiology laboratory personnel, and MRSA isolates were identified using the VITEK 2 system (bioMérieux). Methicillin resistance was confirmed using cefoxitin (30 mg) disk diffusion susceptibility testing according to the guidelines of the Clinical and Laboratory Standards Institute.^[@bibr12-0300060518777812]^

Definitions of colonization and infection {#sec5-0300060518777812}
-----------------------------------------

MRSA colonization was assumed based upon the isolation of MRSA from that patient's nasal swab. MRSA colonization was reported as ICU-acquired only if the patient had an MRSA-positive nasal swab that was collected at least 48 hours after ICU admission, no history of prior colonization or infection at West China Hospital, and no MRSA-positive swabs or clinical samples within 48 hours of admission. MRSA infection was diagnosed in patients with an MRSA-positive clinical sample. ICU-acquired MRSA infection was defined as the development of MRSA infection at least 48 hours after ICU admission. The incidence of MRSA infection was reported per 100 patients.

Review of Chinese data {#sec6-0300060518777812}
----------------------

The following major electronic databases were systematically searched: China National Knowledge Infrastructure (CNKI) database, Chinese Biomedical Literature database (CBM), Chinese VIP database, Chinese Wanfang database, and Medline database. The search terms were "'MRSA' OR 'methicillin-resistant *Staphylococcus aureus*,'" "'active surveillance' OR 'nasal colonization,'" and "'ICU' OR 'intensive care unit.'" The search location was restricted to mainland China.

Statistical analysis {#sec7-0300060518777812}
--------------------

Microsoft Excel 2010 (Microsoft Corporation, Redmond, WA, USA) was used to manage the data. Statistical analyses were performed using PASW Statistics, version 18.0 (SPSS Inc., Chicago, IL, USA). Because our continuous data did not follow a normal probability distribution using the Kolmogorov--Smirnov test, they are expressed as medians along with 25th and 75th percentiles and were analyzed using the Mann--Whitney U-test. Categorical data are presented as number and percentage and were analyzed using the chi-square test or Fisher's exact test. All tests were two-tailed, and a P-value of \<0.05 was considered significant.

Because this study was only an epidemiological survey, no intervening measures were enforced on any patients. The ethics committee of West China Hospital approved the study and waived the need for informed consent.

Results {#sec8-0300060518777812}
=======

During the study period, 2853 patients were admitted to the ICU. Of those admitted, 14 (0.5%) had an MRSA infection within 48 hours of admission, while 64 (2.2%) did not have a nasal swab collected within 48 hours of ICU admission. During the study period, 554 patients (20.0%) were discharged within 3 days and 2221 patients (77.8%) remained in the ICU for more than 3 days,; of these 2221 patients, 1727 (77.8%) were sampled at discharge according to the study protocol.

Therefore, 2775 patients (97.3%) were screened for MRSA on ICU admission. Their mean age was 56.6 ± 19.3 years, and the male:female ratio was 1.8:1.0 (64.8%:35.2%). A total of 115 patients (4.1%; 95% confidence interval \[CI\], 3.4--4.9) had nasal MRSA colonization. There were no significant differences in demographic characteristics or underlying diseases between patients with and without MRSA colonization. The ICU LOS, hospital expenses, and mortality rates were not significantly different between patients with and without MRSA colonization ([Table 1](#table1-0300060518777812){ref-type="table"}). A total of 47 patients (1.7%; 95% CI, 1.2--2.2) acquired MRSA infections in the ICU during the study period. Patients with MRSA colonization on admission were more likely to develop an MRSA infection than those without (4.3% vs. 1.6%, respectively; odds ratio \[OR\], 2.8; 95% CI, 1.1--7.3). The MRSA infection rate in 2011, 2012, and 2013 was 2.2% (95% CI, 1.2--3.2), 2.0% (95% CI, 1.2--2.9), and 0.8% (95% CI, 0.2--1.4), respectively (linear-by-linear association, 5.04; P = 0.02).

###### 

Characteristics and outcomes of MRSA-positive and -negative patients on ICU admission.

![](10.1177_0300060518777812-table1)

  Characteristics                    MRSA-negative (n = 2660)   MRSA-positive (n = 115)   *Z/χ ^*2*^*   P-value
  ---------------------------------- -------------------------- ------------------------- ------------- ---------
  Demographics                                                                                          
  Sex                                                                                                   
   Male                              1728 (65.0)                71 (61.7)                               
   Female                            932 (35.5)                 44 (38.3)                 0.50          0.48
  Age, years                                                                                            
   Mean ± standard deviation         56.6 ± 19.2                56.2 ± 20.3               2.21          0.14
   Median (range)                    58.3 (0--98)               56.5 (13--89)                           
  Pre-ICU LOS, days                                                                                     
   Mean                              6.7                        6.2                                     0.67
  Underlying disease                                                                                    
   COPD                              346 (13.0)                 21 (18.3)                 2.65          0.10
   Coma                              24 (0.9)                   3 (2.6)                                 0.10
   Heart failure                     146 (5.5)                  9 (7.8)                   1.14          0.29
   Renal failure                     238 (8.9)                  13 (11.3)                 0.74          0.39
   Diabetes mellitus                 150 (5.6)                  6 (5.2)                   0.04          0.89
   Hypertension                      248 (9.3)                  17 (14.8)                 3.80          0.05
   Respiratory failure               552 (20.8)                 27 (23.5)                 0.50          0.48
   Cancer                            338 (12.7)                 13 (11.3)                 0.20          0.69
   Blood disease                     41 (1.5)                   2 (1.7)                                 0.69
  Prior invasive procedure                                                                              
   Mechanical ventilation            672 (25.3)                 32 (27.8)                 0.38          0.54
   Central venous catheterization    194 (7.3)                  11 (9.6)                  0.83          0.36
   Urinary catheterization           547 (20.6)                 23 (20.0)                 0.02          0.88
   Dialysis                          42 (1.6)                   3 (2.6)                                 0.43
   Surgery                           698 (26.2)                 27 (23.5)                 0.44          0.51
  Outcome                                                                                               
   MRSA infection                    42 (1.6)                   5 (4.3)                                 0.04
  Length of stay in ICU, days                                                                           
   Median (range)                    8.9 (1--646)               9.8 (1--102)              0.07          0.79
   Mean ± standard deviation         14.6 ± 22.2                15.2 ± 17.7               0.26          0.79
  Mortality (%)                      376 (14.1)                 16 (13.9)                 0.00          0.95
  Hospital charges, median (range)   67,306 (736--1,075,038)    56,519 (1586--525,564)    0.63          0.43

Data are presented as n (%) unless otherwise indicated. MRSA, methicillin-resistant *Staphylococcus aureus*; ICU, intensive care unit; LOS, length of stay; COPD, chronic obstructive pulmonary disease.

A total of 2221 of 2775 patients stayed in the ICU for more than 3 days, among whom 91 had MRSA colonization on admission. Among the remaining 2130 patients, 1727 (81.1%) were sampled at discharge and 185 (10.7%; 95% CI, 9.3--12.2) had acquired MRSA colonization during their ICU stay. The incidence of MRSA colonization while in the ICU was much higher than that on admission. Risk factors for acquiring MRSA colonization in the ICU included having chronic obstructive pulmonary disease, being on mechanical ventilation, and receiving dialysis (P \< 0.05) ([Table 2](#table2-0300060518777812){ref-type="table"}). The mean ICU LOS for patients with MRSA colonization was 23.3 days, which was significantly longer than that for patients without MRSA colonization (15.1 days, P = 0.00). The mean overall expense for MRSA-colonized patients was also significantly higher than that for patients without (135,171.0 vs. 107,209.3 Yuan, respectively; P = 0.00). However, the mortality rates between the two groups were not significantly different. Among the 185 patients with MRSA colonization at discharge, 20 (10.8%; 95% CI, 6.3--15.3) had acquired an MRSA infection during their ICU stay, which was significantly more than those without MRSA colonization at discharge (0.9%; 95% CI, 0.4--1.4; P = 0.00).

###### 

Characteristics and outcomes of MRSA-positive and -negative patients at ICU discharge.

![](10.1177_0300060518777812-table2)

  Characteristics                    MRSA-negative (n = 1542)       MRSA-positive (n = 185)          *Z/χ ^*2*^*   P-value
  ---------------------------------- ------------------------------ -------------------------------- ------------- ---------
  Demographics                                                                                                     
  Sex                                                                                                              
   Male                              1022 (66.3)                    110 (59.5)                       3.40          0.07
   Female                            520 (33.7)                     75 (40.5)                                      
  Age, years                                                                                                       
   Mean ± standard deviation         57.1 ± 19.1                    58.5 ± 18.5                      0.84          0.36
   Median (range)                    59 (4--98)                     61 (15--90)                                    
  Pre-ICU LOS, days                                                                                                
   Mean                              6.8±14.1                       6.8 ± 13.7                       0.00          0.99
  Underlying disease                                                                                               
   COPD                              244 (15.8)                     42 (22.7)                        5.66          0.02
   Coma                              15 (1.0)                       2 (1.1)                          0.02          0.89
   Heart failure                     95 (6.2)                       10 (5.4)                         0.16          0.69
   Renal failure                     146 (9.5)                      19 (10.3)                        0.12          0.73
   Diabetes mellitus                 97 (6.3)                       16 (8.6)                         1.50          0.22
   Hypertension                      183 (11.9)                     22 (11.9)                        0.00          0.99
   Respiratory failure               389 (25.2)                     44 (23.8)                        0.18          0.67
   Cancer                            190 (12.3)                     10 (5.4)                         7.72          0.01
   Blood disease                     17 (1.1)                       2 (1.1)                          0.00          0.98
  Prior invasive procedure                                                                                         
   Mechanical ventilation            922 (59.8)                     151 (81.6)                       33.45         0.00
   Central venous catheterization    637 (41.3)                     76 (41.1)                        0.01          0.95
   Urinary catheterization           1392 (90.3)                    175 (94.6)                       3.67          0.06
   Dialysis                          121 (7.8)                      29 (15.7)                        12.76         0.00
   Surgery                           395 (25.6)                     27 (14.6)                        10.87         0.00
  Outcome                                                                                                          
   MRSA infection                    14 (0.9)                       20 (10.8)                        89.93         0.00
  Length of stay in ICU                                                                                            
   Median (range), days              10 (4--159)                    15 (4--128)                                    
   Mean ± standard deviation         15.1 ± 15.9                    23.3 ± 23.3                      39.03         0.00
  Mortality (%)                      214 (13.9)                     26 (14.1)                        0.01          0.95
  Hospital charges, mean             107,209.3 ± 97,731.9           135,171.0 ± 137,902.0            12.06         0.00
  Hospital charges, median (range)   76,005.7 (4345.0--816,052.2)   86,326.9 (15,896.6--818,153.7)                 

Data are presented as n (%) unless otherwise indicated. MRSA, methicillin-resistant *Staphylococcus aureus*; ICU, intensive care unit; LOS, length of stay; COPD, chronic obstructive pulmonary disease.

Discussion {#sec9-0300060518777812}
==========

This study revealed that 4.1% of patients admitted to West China Hospital's ICU were already colonized with MRSA on admission. Our review of existing data from China revealed nine papers that were published in Chinese and one paper describing a study that was conducted in mainland China but published in the English version of a Chinese journal.^[@bibr14-0300060518777812][@bibr15-0300060518777812][@bibr16-0300060518777812][@bibr17-0300060518777812][@bibr18-0300060518777812][@bibr19-0300060518777812][@bibr20-0300060518777812][@bibr21-0300060518777812][@bibr22-0300060518777812]--[@bibr23-0300060518777812]^ The total number of patients included in the 10 articles was 3798, and the percentage of patients already colonized with MRSA on ICU admission ranged from 3.0% to 11.0% (median, 7.9%; 25%--75% interquartile range, 4.2--9.1) ([Table 3](#table3-0300060518777812){ref-type="table"}). Similarly, studies in other countries reported that 4.9% to 13.1% of ICU patients are already colonized with MRSA on admission.^[@bibr7-0300060518777812],[@bibr24-0300060518777812][@bibr25-0300060518777812]--[@bibr26-0300060518777812]^ The variation in the prevalence of MRSA colonization is likely due to regional differences, as previous studies have demonstrated. In Asia, Izumikawa et al.^[@bibr26-0300060518777812]^ reported that 7.5% of patients in an ICU in Japan had MRSA colonization on admission, while another study involving 342 ICU patients in Korea found that the prevalence of MRSA colonization on admission was 27.5%.^[@bibr27-0300060518777812]^ Even in North America, studies have reported remarkable differences. For instance, Ridenour et al.^[@bibr25-0300060518777812]^ discovered a relatively high proportion of MRSA-colonized patients on ICU admission (11.0%), while Davis et al.^[@bibr28-0300060518777812]^ demonstrated a relatively low proportion (3.4%).

###### 

Characteristics of selected Chinese studies.

![](10.1177_0300060518777812-table3)

  First Author     Journal                           Publication Year   Vol (Issue):Pages    Location    Unit                                 MRSA colonization on admission   MRSA colonization at discharge   Reference                     
  ---------------- --------------------------------- ------------------ -------------------- ----------- ------------------------------------ -------------------------------- -------------------------------- ----------- ----- ---- ------ --------
  Zhou Chun-mei    *Chin J Nosocomiol*               2011               21(12):2592--2594    Shanghai    ICU                                  211                              9                                4.3         211   26   12.3   \[14\]
  Fan Shan-hong    *Chin J Infect Control*           2015               14(3):174--177       Xi\'an      ICU/RICU/NSICU                       197                              18                               9.1         179   4    2.2    \[15\]
  Gu Ke-ju         *Chin J Infect Control*           2016               15(6):401--404       Shanghai    ICU                                  240                              22                               9.2         218   34   15.6   \[16\]
  Zou Xiaoni       *Modern Hospital Jul*             2013               13(7):65--67         Guangdong   NICU, neonatal intensive care unit   429                              28                               6.5                           \[17\]
  Li Qiang         *Chin Med J (Engl)*               2014               127(10):1804--1807   Beijing     ICU                                  350                              31                               8.9                           \[18\]
  Xie Yi           *J Trop Med*                      2014               14(2):223--225       Guangdong   ICU                                  79                               3                                3.8                           \[19\]
  Zhang Yan-qing   *Chin J Infect Control*           2014               13(11):650--653      Fujian      SICU                                 100                              11                               11.0                          \[20\]
  Zheng Xuan\'er   *Chin J Obstet Gynecol Pediatr*   2014               10(3):328--332       Guangdong   NICU, neonatal intensive care unit   581                              41                               7.1                           \[21\]
  Meng Li-hui      *Chin J Nosocomiol*               2015               25(21):4965--4967    Beijing     ICU                                  238                              21                               8.8                           \[22\]
  Gu Ji-na         *Chin J Nosocomiol*               2015               25(11):2481--2483    Zhejiang    ICU                                  1373                             41                               3.0                           \[23\]

MRSA, methicillin-resistant *Staphylococcus aureus*; ICU, intensive care unit; RICU, respiratory intensive care unit; NSICU, neurological surgical intensive care unit; SICU, surgical intensive care unit.

Differences in sample size proportions are another possible reason for the variations in prevalence. Honda et al.^[@bibr24-0300060518777812]^ proposed that such differences may significantly influence results. In their study, the nasal swab sampling percentage was as high as 98.9%, while other studies had a lower nasal swab percentage. Another possible reason for the differences in colonization data is sampling site selection. Previous studies have shown that the sensitivity of MRSA surveillance cultures was significantly higher in throat and tracheal aspirates (82%) than in anterior nares (47%).^[@bibr29-0300060518777812]^ A study in Taiwan revealed that the MRSA screening sensitivity also depended on the anatomic location of sampling, number of sites cultured, culture methods, and distribution of strain types.^[@bibr30-0300060518777812]^

Our study showed that 10.7% of patients became colonized with MRSA during their ICU stay. This result is similar to those found in previous studies in other countries (4.9%--15.0%).^[@bibr31-0300060518777812][@bibr32-0300060518777812]--[@bibr33-0300060518777812]^ However, after we searched the Chinese-language literature database, only 3 studies provided discharge data, in which 64 ICU patients became MRSA-colonized at percentages ranging from 2.2% to 15.6%.^[@bibr14-0300060518777812][@bibr15-0300060518777812]--[@bibr16-0300060518777812]^ Our results are slightly lower than those of two previous studies published in China,^[@bibr14-0300060518777812],[@bibr16-0300060518777812]^ both of which had a small sample size and unclear MRSA acquisition rates. Our large sample size and the high incidence of nasal-swab culture collection over a 3-year study period are major strengths of our study. As many previous studies have demonstrated, our study also showed that patients were more likely to be colonized with MRSA if they underwent mechanical ventilation, received dialysis, or had chronic obstructive pulmonary disease.

Our study confirmed that patients already colonized with MRSA on admission were more likely to acquire MRSA infection (2.3-fold higher risk; 95% CI, 1.1--7.3) than those who had not been colonized, although our percentages were lower than those reported in previous studies (5.9-, 9.5- and 107.7-fold).^[@bibr28-0300060518777812],[@bibr34-0300060518777812],[@bibr35-0300060518777812]^ The different types of ICUs and different prevalences of MRSA in different areas may account for these variations in study results. In our study, 1.7% of patients developed MRSA infections during their ICU stay, which is similar to the findings reported by Milstone et al.^[@bibr34-0300060518777812]^ (1.8%). This suggests a low incidence of MRSA infection in our ICU.

Our study also revealed that the healthcare associated MRSA infection rate decreased significantly from 2.2% (95% CI, 1.2--3.2) in 2011 to 0.8% (95% CI, 0.2--1.4) in 2013, which is also consistent with a few studies that have shown correlations between the presence of an active surveillance program and reduced MRSA infection rates.^[@bibr36-0300060518777812]^ It appears that ASC programs and their data are helpful in reducing ICU MRSA infection rates. However, the voluntary isolation of MRSA-positive patients by clinicians and the hospital's promotion of hand hygiene during the study period may have also contributed to the low MRSA infection rate.

We recognize that our study has several limitations. First, we used ChromID MRSA-Select agar plates to detect MRSA, but previous studies^[@bibr37-0300060518777812],[@bibr38-0300060518777812]^ have reported that these agar plates may have low sensitivity, and both nonselective enrichment broth and semiselective broth containing cefoxitin and aztreonam can improve its sensitivity.^[@bibr39-0300060518777812]^ In contrast, polymerase chain reaction has greater sensitivity for MRSA identification, but because of hospital capacity limitations, we did not use this technique for MRSA screening.^[@bibr40-0300060518777812],[@bibr41-0300060518777812]^ Second, we used only a single sampling site, the nares, which has a lower incidence of MRSA recovery than throat swabs and tracheal aspirates. Sampling multiple sites for culture has also been shown to increase MRSA-detection sensitivity.^[@bibr30-0300060518777812]^ Third, this was an observational study, and we did not compulsorily isolate those colonized with MRSA nor did we decolonize patients due to insufficient capacity, which may partially explain our MRSA colonization prevalence of 10% at discharge.

In conclusion, our study has demonstrated that the prevalence of MRSA colonization was 4.1% on ICU admission and that 10.7% of patients acquired MRSA during their ICU stay. We have also confirmed that patients who already had MRSA colonization on admission were significantly more likely to develop MRSA infections during their ICU stays. ASCs and their resulting data are helpful in reducing MRSA infections.
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